Holen Sie sich die Stockscreener-App
71.33
0.46%
0.33
Schlusskurs vom Vortag:
$71.00
Offen:
$70.48
24-Stunden-Volumen:
2.20M
Relative Volume:
2.17
Marktkapitalisierung:
$1.45B
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-48.86
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
+93.78%
1M Leistung:
+95.00%
6M Leistung:
+177.33%
1J Leistung:
+7,898%
1-Tages-Spanne:
$67.70
$73.37
1-Wochen-Bereich:
$35.59
$73.37
52-Wochen-Spanne:
$0.432
$73.37
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
71.33 | 1.44B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics stock pops on $300M equity offering - MSN
Nektar Therapeutics closes $460 million public offering By Investing.com - Investing.com India
Nektar Therapeutics prices $400M stock offering - MSN
Nektar Therapeutics Secures Major Funding as Shares Rally - AD HOC NEWS
Nektar Therapeutics closes $460 million public offering - Investing.com
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
Nektar Therapeutics (NKTR) Is Up 88.9% After Upsized Equity Raise And Positive REZOLVE-AD DataHas The Bull Case Changed? - Sahm
Can NKTR Stock Sustain Its 1,000% Rally? - Forbes
Nektar Stock: $400M Dilution And A Make-Or-Break Phase 3 - Trefis
Nektar Therapeutics Prices Upsized Public Equity Offering - TipRanks
Nektar Therapeutics stock hits 52-week high at 66.97 USD By Investing.com - Investing.com Nigeria
Nektar Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView
Why Nektar Therapeutics (NKTR) Is Up 102.2% After Strong REZOLVE-AD Data And $400 Million Raise - Yahoo Finance
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar CEO looks to add $400 milllion for atopic dermatitis drug - The Business Journals
Nektar Therapeutics stock falls after $400 million public offering By Investing.com - Investing.com UK
Nektar Therapeutics (NASDAQ:NKTR) Sets New 12-Month HighHere's Why - MarketBeat
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up - simplywall.st
HC Wainwright Expects Lower Earnings for Nektar Therapeutics - MarketBeat
Nektar Therapeutics Prices $400 Million Offering of Stock, Pre-Funded Warrants - marketscreener.com
Nektar Therapeutics (NKTR) Finalizes $400M Stock Offering - GuruFocus
Nektar Therapeutics announces pricing of upsized $400 million public offering - marketscreener.com
Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public Offering - TradingView
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering - The Malaysian Reserve
Rezpegaldesleukin maintenance data show durable responses in moderate-to-severe atopic dermatitis - Contemporary Pediatrics
Nektar Stock Soars Amid Promising Developments and Analyst Upgrades - StocksToTrade
Nektar seeks US$300m for promising eczema drug - ifr-logo
Nektar Therapeutics stock hits 52-week high at 66.97 USD - Investing.com
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means - Seeking Alpha
Nektar’s Rezpegaldesleukin Shows Promise, Analysts Raise Price Targets - timothysykes.com
Nektar Therapeutics (NASDAQ:NKTR) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
BTIG Lifts Nektar Price Target Amidst Promising Atopic Dermatitis Treatment - StocksToTrade
Nektar Therapeutics (NKTR) Shares Surge on $300M Public Offering Announcement - GuruFocus
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? - Nasdaq
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage - BioSpace
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $102 to $165 - 富途牛牛
Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data - Citeline News & Insights
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win - Yahoo Finance
Q3 EPS Forecast for Nektar Therapeutics Boosted by Analyst - MarketBeat
Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine
Nektar Therapeutics (NKTR) stock jumps again premarket after 51% surge; $300 million offering in focus - Bez Kabli
Nektar reports positive long-term data for atopic dermatitis drug By Investing.com - Investing.com South Africa
Nektar lands upsized US$400m for eczema drug - ifr-logo
Nektar Therapeutics announces $300 million public offering By Investing.com - Investing.com South Africa
Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 - MarketBeat
BTIG Maintains Buy on Nektar Therapeutics (NKTR) Feb 2026 - Meyka
Nektar Therapeutics (NKTR) Launches $300M Stock Offering - GuruFocus
Nektar Therapeutics stock price target raised to $151 by BTIG - Investing.com UK
Evommune, Nektar assets join list of recent successes in atopic derm - biocentury.com
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):